US Patent 9,850,229: Encorafenib and MEK-Inhibitor Combination Patent Landscape
US Patent 9,850,229 protects methods of treating melanoma by detecting a mutant BRAF kinase and administering encorafenib with a MEK inhibitor. The claims cover both sequential and concurrent administration, non-fixed combinations, BRAF V600E melanoma, metastatic melanoma, capsule formulations, and a defined group of MEK inhibitors. The commercially important embodiment is oral encorafenib, marketed as Braftovi, combined with binimetinib, marketed as Mektovi.
The patent is a method-of-use patent. It does not claim encorafenib as a chemical compound, binimetinib as a compound, or a fixed-dose combination product.
What patent is US 9,850,229?
US Patent 9,850,229 is directed to combination treatment of BRAF-mutant melanoma with a BRAF inhibitor and a MEK inhibitor.
| Field |
Detail |
| Patent |
US 9,850,229 B2 |
| Grant date |
December 26, 2017 |
| Technology |
BRAF inhibitor plus MEK inhibitor |
| BRAF inhibitor |
Encorafenib, also known as LGX818 |
| Commercial product |
Braftovi |
| Primary indication |
BRAF-mutant melanoma |
| Commercial MEK partner |
Binimetinib, also known as ARRY-438162 |
| Commercial product |
Mektovi |
| Claim category |
Method of treatment |
| Administration |
Oral encorafenib; sequential or concurrent MEK inhibitor |
| Assignee history |
Array BioPharma-related patent ownership; Array was acquired by Pfizer in 2019 |
| FDA combination approval |
June 27, 2018 |
The compound identified in the claims is encorafenib, chemically described as methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate.
FDA approved Braftovi in combination with Mektovi for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. The combination approval followed the COLUMBUS clinical development program.[1]
What does claim 1 of US 9,850,229 cover?
Claim 1 has four operative elements:
- The patient has melanoma.
- A mutant BRAF kinase is detected in the melanoma.
- Encorafenib or a pharmaceutically acceptable salt is orally administered.
- A pharmaceutical composition containing a MEK inhibitor is also administered.
The claim does not require:
- A particular encorafenib dose.
- A particular binimetinib dose.
- A fixed-dose tablet containing both active ingredients.
- A specified treatment sequence.
- A specific mutation in the independent claim.
- Metastatic disease in the independent claim.
- A specific MEK inhibitor.
- A specific biomarker assay.
The detection requirement is important. A treatment protocol that administers encorafenib and a MEK inhibitor without detecting mutant BRAF may present a non-infringement position against the literal language of claim 1, depending on the facts and the doctrine of equivalents.
The phrase "therapeutically effective amount" is a standard functional limitation. It requires that the administered quantities be effective to treat the claimed condition, but it does not impose a specific numerical dose.
How do claims 2 through 20 narrow the patent scope?
The dependent claims divide the invention into administration format, mutation status, disease stage, MEK inhibitor identity, and dosage form.
| Claims |
Limitation |
| 1 |
Detect mutant BRAF; orally administer encorafenib and a MEK inhibitor |
| 2 |
Non-fixed combination |
| 3 |
Sequential administration |
| 4 |
BRAF V600E melanoma |
| 5 |
Specified MEK inhibitor list |
| 6 |
ARRY-438162, now binimetinib |
| 7 |
Encorafenib composition formulated as a capsule |
| 8 |
Sequential binimetinib combination with encorafenib capsule |
| 9 |
Concurrent administration |
| 10 |
Concurrent treatment of BRAF V600E melanoma |
| 11 |
Specified MEK inhibitor list |
| 12 |
Concurrent binimetinib treatment |
| 13 |
Encorafenib capsule in the concurrent regimen |
| 14 |
Concurrent binimetinib treatment with encorafenib capsule |
| 15 |
Metastatic melanoma |
| 16-17 |
Metastatic BRAF V600E melanoma with listed MEK inhibitor, particularly binimetinib |
| 18-20 |
Metastatic melanoma under the concurrent-treatment branch, particularly with binimetinib |
Claims 8, 14, and 17 are commercially important because they narrow the claim set toward the Braftovi-Mektovi regimen. Claims 15 through 20 add metastatic disease, which corresponds closely to the principal labeled use of the combination.
Claim 13 contains the phrase "The method of 9" rather than "The method of claim 9." That appears to be a drafting or transcription error. Its substantive dependency is apparent from the claim structure, but the precise legal effect should be evaluated against the issued patent, prosecution history, and any certificate of correction.
Which MEK inhibitors are listed in US 9,850,229?
Claims 5 and 11 list the following compounds:
| Code |
Identity or development status |
| AS703026 |
Pimasertib |
| MSC1936369B |
PD-0325901-related MEK inhibitor designation |
| GSK1120212 |
Trametinib |
| AZD6244 |
Selumetinib |
| PD-0325901 |
MEK inhibitor |
| ARRY-438162 |
Binimetinib |
| RDEA119 |
Refametinib |
| GDC0941 |
Pictilisib, primarily a PI3K inhibitor designation |
| GDC0973 |
Cobimetinib |
| TAK-733 |
MEK inhibitor |
| RO5126766 |
Dual RAF/MEK inhibitor |
| XL-518 |
Cobimetinib-related development designation |
The list does not limit the independent claim. Claim 1 recites a MEK inhibitor without naming one. The dependent claims provide selected species.
GDC0941 is notable because it is generally associated with PI3K inhibition rather than conventional MEK inhibition. The claim nevertheless includes it in the enumerated list. That discrepancy could become relevant in claim construction, written-description, enablement, or validity analysis, but it does not automatically remove the compound from the issued claim language.
Does US 9,850,229 cover Braftovi and Mektovi?
Yes. The commercial Braftovi-Mektovi regimen falls within the core technical disclosure and the narrow dependent-claim architecture:
- Braftovi contains encorafenib.
- Mektovi contains binimetinib.
- Binimetinib is ARRY-438162.
- Both products are orally administered.
- Braftovi is supplied in capsule form.
- The approved indication includes BRAF V600E or V600K unresectable or metastatic melanoma.
- The products are marketed as separate, non-fixed dosage forms.
The patent does not require the products to be packaged together. Claims 2 and 3 expressly address non-fixed and sequential administration. Claims 9 through 14 address concurrent administration.
What is the difference between the sequential and concurrent claims?
The patent creates two principal infringement branches.
Sequential administration
Claims 3 through 8 cover sequential administration. The claims do not state which product must be administered first. A regimen may therefore fall within the literal wording whether encorafenib precedes binimetinib or binimetinib precedes encorafenib, subject to the construction of "sequentially" and the factual timing of administration.
Claims 4 through 8 narrow the sequential branch to:
- BRAF V600E melanoma.
- A listed MEK inhibitor.
- Binimetinib in claim 6.
- An encorafenib capsule in claims 7 and 8.
Concurrent administration
Claims 9 through 14 cover concurrent administration. They similarly narrow through BRAF V600E status, the listed MEK inhibitor group, binimetinib, and the encorafenib capsule.
"Concurrent" does not necessarily require simultaneous swallowing of both products. In pharmaceutical claim construction, the term may encompass administration within a clinically coordinated treatment period, but the exact scope depends on the intrinsic record and the court's construction.
What formulation patents are relevant?
US 9,850,229 protects a treatment method and only reaches a formulation through dependent claims 7, 8, 13, and 14, which require the encorafenib composition to be formulated as a capsule.
It does not independently claim:
- The Braftovi capsule composition as a composition of matter.
- A particular excipient system.
- A specific dissolution profile.
- A manufacturing process.
- A fixed-dose Braftovi-Mektovi tablet.
- The Mektovi tablet formulation.
Other patent families may protect the encorafenib molecule, crystalline forms, salts, pharmaceutical compositions, manufacturing processes, or particular uses. Those rights must be separated from the combination-treatment rights in US 9,850,229.
When does US 9,850,229 lose patent exclusivity?
The patent was granted on December 26, 2017. Its statutory term is generally calculated from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment and any terminal disclaimer. Public patent records associate the family with a 2012 priority chain and a 2013 international or nonprovisional filing period. On that basis, the ordinary statutory expiration is expected in 2033, before any applicable patent-term adjustment.
The operative expiration date should be taken from the USPTO patent record and the Orange Book listing because:
- Patent-term adjustment can extend the term.
- A terminal disclaimer can shorten the term.
- Patent-term extension under 35 U.S.C. ยง 156 is distinct from patent-term adjustment.
- The patent may have related continuation patents with later expiration dates.
- An Orange Book-listed patent may have a separate use code and expiry entry.
The commercial exclusivity position for Braftovi is therefore not determined by US 9,850,229 alone.
What is the Orange Book status of US 9,850,229?
US 9,850,229 is relevant to the Braftovi NDA, FDA application 210496, because it claims a method corresponding to the approved combination use of encorafenib with a MEK inhibitor.
For Orange Book analysis, the key distinction is between:
- Patent listing against Braftovi.
- Patent listing against Mektovi.
- Use codes covering encorafenib alone.
- Use codes covering encorafenib with binimetinib.
- Composition and formulation patents.
- Method-of-use patents with later expiration dates.
An ANDA applicant seeking approval for encorafenib for the protected combination indication could face a Paragraph IV issue if the patent remains listed and unexpired. A generic applicant seeking only an unprotected encorafenib indication could use a section viii statement, where legally available, to carve out the protected combination use.
A Paragraph IV certification is not itself an infringement finding. The patent holder would need to bring a timely action under the Hatch-Waxman framework to obtain the statutory 30-month stay.
Which companies are challenging US 9,850,229?
The principal commercial rights holder is Pfizer through its acquisition of Array BioPharma. No widely reported final federal invalidity judgment or publicly established generic settlement concerning US 9,850,229 is identified in the principal FDA and patent sources reviewed for this analysis.
The absence of a reported challenge does not eliminate future ANDA risk. The relevant trigger would be an ANDA filing for encorafenib, an ANDA for the protected combination use, or a litigation disclosure by Pfizer, the NDA holder, or a generic applicant.
What patent litigation affects Braftovi and Mektovi?
The most important litigation risk is likely to arise from future generic encorafenib filings rather than from biosimilar litigation. Braftovi and Mektovi are small-molecule drugs, so biosimilar procedures under the Biologics Price Competition and Innovation Act do not apply.
Potential litigation theories include:
- Paragraph IV invalidity.
- Non-infringement based on omission of mutant-BRAF detection.
- Non-infringement based on an indication carve-out.
- Non-infringement based on a non-listed MEK inhibitor.
- Obviousness of BRAF-MEK combination therapy.
- Written-description or enablement challenges to the broad MEK-inhibitor language.
- Patent-term or terminal-disclaimer disputes.
- Orange Book listing disputes.
A generic product that uses encorafenib with binimetinib for metastatic BRAF-mutant melanoma would face the highest exposure under claims 4 through 20. A product labeled only for an unprotected use could reduce method-of-use exposure through labeling design, although induced-infringement risk would depend on actual marketing conduct.
How strong is the patent estate for encorafenib?
The estate is strongest when assessed as a layered portfolio rather than through US 9,850,229 alone.
| Protection layer |
Strategic value |
| Encorafenib compound patents |
Protect the active molecule across indications |
| Salt and solid-form patents |
Restrict alternative pharmaceutical forms |
| Formulation patents |
Protect capsule composition and performance attributes |
| Manufacturing patents |
Raise supply-chain and process-design barriers |
| Melanoma method patents |
Protect BRAF-mutant melanoma treatment |
| Combination patents |
Protect encorafenib plus MEK-inhibitor use |
| FDA exclusivity |
Provides regulatory protection independent of patent validity |
| Orange Book listings |
Enable Hatch-Waxman litigation and potential stay |
US 9,850,229 is commercially meaningful because the claimed regimen corresponds to the product's central differentiated use. Its vulnerability is that combination treatment of BRAF-mutant melanoma was an active field with multiple prior-art combinations involving BRAF and MEK inhibition. Obviousness, motivation to combine, clinical predictability, and the scope of the disclosed evidence would be central validity issues.
The patent is less effective against:
- Encorafenib monotherapy.
- Encorafenib with an unlisted non-MEK partner.
- Competing BRAF inhibitors.
- Competing BRAF-MEK combinations that do not use encorafenib.
- Uses outside melanoma.
- Products sold with a lawful indication carve-out.
How does US 9,850,229 compare with competing BRAF-MEK patents?
| Regimen |
BRAF component |
MEK component |
Relevance to US 9,850,229 |
| Braftovi-Mektovi |
Encorafenib |
Binimetinib |
Directly targeted |
| Tafinlar-Mekinist |
Dabrafenib |
Trametinib |
Not a literal encorafenib regimen |
| Zelboraf-Cotellic |
Vemurafenib |
Cobimetinib |
Not a literal encorafenib regimen |
| Braftovi monotherapy |
Encorafenib |
None |
Outside the combination requirement |
| Encorafenib plus investigational MEK inhibitor |
Encorafenib |
Other MEK inhibitor |
Potentially within claim 1 |
The patent therefore protects the BRAF component by chemical identity and the partner component by functional class in the independent claim. That is broader than protection limited solely to binimetinib.
What generic entry risks exist?
Generic entry risk has three distinct scenarios.
Encorafenib monotherapy
A generic seeking approval for an encorafenib monotherapy indication may avoid the central combination claims if its labeling excludes the protected combination use and its conduct does not encourage the patented regimen.
Encorafenib plus binimetinib
This is the highest-risk scenario. The regimen maps directly onto the commercial embodiment and the narrow dependent claims. A Paragraph IV challenge would likely target the validity or scope of the combination claims, along with any separate compound, formulation, or use patents listed for Braftovi.
Encorafenib with another MEK inhibitor
Claim 1 is potentially broad enough to reach encorafenib with a MEK inhibitor other than binimetinib. Claims 5 and 11 provide narrower species claims but do not necessarily limit claim 1. The exposure would depend on the proposed label, actual marketing, and construction of the mutant-BRAF detection requirement.
What are the manufacturing and geographic barriers?
US 9,850,229 does not claim a manufacturing process. Manufacturing barriers arise from separate process, intermediate, solid-form, formulation, and supply-chain patents.
Geographically, the US patent has no direct effect outside the United States. Parallel patent families may exist in Europe, Japan, Canada, Australia, and other markets. The scope and expiry of those rights must be assessed separately because:
- National-phase claims may differ.
- Patent-term rules vary.
- Supplementary protection certificates may apply in Europe.
- Orange Book mechanics are unique to the United States.
- Regulatory exclusivity periods differ by jurisdiction.
A US freedom-to-operate conclusion cannot be extended to non-US markets based solely on US 9,850,229.
Key Takeaways
- US 9,850,229 is a method-of-treatment patent covering oral encorafenib with a MEK inhibitor for mutant-BRAF melanoma.
- The commercial Braftovi-Mektovi regimen is the primary practical embodiment.
- Claims cover non-fixed, sequential, and concurrent administration.
- Dependent claims narrow to BRAF V600E melanoma, metastatic melanoma, binimetinib, and encorafenib capsules.
- The patent does not claim encorafenib or binimetinib as chemical compounds.
- The patent does not cover dabrafenib-trametinib or vemurafenib-cobimetinib as literal regimens.
- The expected ordinary patent-term endpoint is in 2033, subject to USPTO term adjustment and any terminal disclaimer.
- Generic risk is highest for encorafenib products labeled for combination treatment with binimetinib.
- Biosimilar litigation is not relevant because Braftovi and Mektovi are small-molecule drugs.
- Separate compound, formulation, manufacturing, FDA-exclusivity, and Orange Book rights must be evaluated with this patent.
FAQs
Does US 9,850,229 cover encorafenib monotherapy?
No. The independent claim requires administration of encorafenib together with a pharmaceutical composition comprising a MEK inhibitor.
Does the patent require binimetinib?
No. Claim 1 recites a MEK inhibitor generally. Binimetinib, identified as ARRY-438162, is specified in narrower dependent claims.
Does the patent cover BRAF V600K melanoma?
The independent claim covers melanoma with a mutant BRAF kinase. The listed dependent claims specifically identify BRAF V600E. FDA approval of Braftovi-Mektovi includes BRAF V600E or V600K melanoma, but the regulatory label and patent claim scope are separate questions.
Is Braftovi-Mektovi a fixed-dose combination under this patent?
No. Braftovi and Mektovi are separate products. The claims expressly cover non-fixed combinations.
Can a generic avoid the patent by removing the combination indication?
Potentially, depending on the final label, promotional conduct, Orange Book listings, and the facts supporting induced infringement. A label carve-out does not automatically eliminate all infringement exposure.
